Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov;27(Suppl 3):S144-S151.
doi: 10.3747/co.27.7171. Epub 2020 Nov 1.

Current locoregional therapies and treatment strategies in hepatocellular carcinoma

L Cardarelli-Leite  1 , A Hadjivassiliou  2 , D Klass  2 , J Chung  2 , S G F Ho  2 , H J Lim  3 , P T W Kim  4 , A Mujoomdar  1 , D M Liu  2
Affiliations
Review

Current locoregional therapies and treatment strategies in hepatocellular carcinoma

L Cardarelli-Leite et al. Curr Oncol. 2020 Nov.

Abstract

Locoregional therapies (lrts) play an important role in the treatment of hepatocellular carcinoma (hcc), with the aim of increasing overall survival while preserving liver function. Various forms of lrt are available, and choosing the best one depends on technical aspects, liver morphology, tumour biology, and the patient's symptoms. The purpose of the present review article is to provide an overview of the current evidence relating to the use of percutaneous ablation, transarterial chemoembolization, and transarterial radioembolization for the curative or palliative treatment of hcc. Special situations are also reviewed, including the combined use of systemic therapy and lrt, indications and techniques for bridging to transplant and downstaging, and the use of lrt to treat patients with hcc and macrovascular invasion.

Keywords: Hepatocellular carcinoma; chemoembolization; interventional radiology; radiofrequency ablation; transarterial radioembolization.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST DISCLOSURES We have read and understood Current Oncology’s policy on disclosing conflicts of interest, and we declare the following interests: HJL has received fees as an advisory board member for Eisai, Taiho, Merck, Bristol Myers Squibb, Roche, and Ipsen. AM has received speaker fees from Boston Scientific, Terumo Medical, Teleflex, and Medtronic, and fees as an advisory board member for Boston Scientific. DML has received speaker fees from Eisai Pharmaceuticals, Ethicon Endocare/Neuwave; fees as an advisory board member for Merit Medical Systems; and research funding from Boston Scientific for a trial in which he was co-investigator. The remaining authors have no conflicts to disclose.

Figures

FIGURE 1
FIGURE 1
(A,B) A large hepatocellular carcinoma centred in the right lobe of the liver (arrow), with ethiodized oil staining after conventional tran sarterial chemoembolization (asterisk), was treated with transarterial radioembolization using lobectomy radiation dosimetry. (C,D) After 16 months of treatment, a significant reduction in the size of the tumour is evident (arrow), with capsular retraction and atrophy of the superior segments of the right lobe of the liver.
See this image and copyright information in PMC

References

    1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in globocan 2012. Int J Cancer. 2015;136:E359–86. doi: 10.1002/ijc.29210. - DOI - PubMed
    1. Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nat Rev Dis Prim. 2016;2:16018. doi: 10.1038/nrdp.2016.18. - DOI - PubMed
    1. Balogh J, Victor D, 3rd, Asham EH, et al. Hepatocellular carcinoma: a review. J Hepatocell Carcinoma. 2016;3:41–53. doi: 10.2147/JHC.S61146. - DOI - PMC - PubMed
    1. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391:1301–14. doi: 10.1016/S0140-6736(18)30010-2. - DOI - PubMed
    1. Burak KW, Sherman M. Hepatocellular carcinoma: consensus, controversies and future directions: a report from the Canadian Association for the Study of the Liver Hepatocellular Carcinoma Meeting. Can J Gastroenterol Hepatol. 2015;29:178–84. doi: 10.1155/2015/824263. - DOI - PMC - PubMed